LXE408 clinical trials
Also written LXE408.
How each study uses LXE408 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LXE408 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LXE408
- 5
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Drugs for Neglected Diseases (3) · Novartis Pharmaceuticals (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test LXE408.
- Jul 2027A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Phase 2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses LXE408 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.RecruitingPhase 2Novartis PharmaceuticalsNCT06632600Written as LXE408
- A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).Not yet recruitingPhase 2Drugs for Neglected DiseasesNCT06997159Written as LXE408
- A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT07809919Written as LXE408
- A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral LeishmaniasisCompletedPhase 2Drugs for Neglected DiseasesNCT05593666Written as LXE408
- LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept StudyCompletedPhase 2Drugs for Neglected DiseasesNCT05957978Written as LXE408
Codes
What other systems call LXE408 · ClinicalTrials.gg INT001506
- MeSH (NLM) C000712276LXE408One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712276 | LXE408 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.